Wave Life Sciences (WVE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.34
- Estimate
- -$0.30
- Surprise
- -14.4%
- Revenue (period 2026-06-30)
- $2.3M
- Score today
- 3.8/10
Revenue source: mixed.
How the report landed
Wave Life Sciences (WVE) reported a wider loss than forecast — diluted EPS of -$0.34 against the -$0.30 estimate (a 14.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates WVE Sell at 3.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -14.4% surprise compares with a +5.6% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $19.06 vs price $4.86 — ratio 3.9×). Rejected, falling back to technical TP.
- Quality below floor (1.8 < 4.0)
- Momentum score 2.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.80
- Price target
- $6.28
- Stop
- $4.52
- Upside to target
- +30.8%
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
WVE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $957.7M
- P/E (fwd)
- -4.1
- 52-week range
- $4.65–$21.73
- Off 52-week high
- 77.9%
- RSI (14)
- 43
- Volume vs avg
- 0.81×
- Score today
- 3.8/10